Heska Corporation (HSKA): Price and Financial Metrics

Heska Corporation (HSKA): $97.55

4.23 (+4.53%)

POWR Rating

Component Grades














  • HSKA scores best on the Sentiment dimension, with a Sentiment rank ahead of 64.8% of US stocks.
  • The strongest trend for HSKA is in Momentum, which has been heading down over the past 179 days.
  • HSKA ranks lowest in Momentum; there it ranks in the 14th percentile.

HSKA Stock Summary

  • HSKA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1,775.6 -- higher than 98.27% of US-listed equities with positive expected earnings growth.
  • Price to trailing twelve month operating cash flow for HSKA is currently 239.64, higher than 97.99% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of 92.27%, Heska Corp's debt growth rate surpasses 89.23% of about US stocks.
  • Stocks that are quantitatively similar to HSKA, based on their financial statements, market capitalization, and price volatility, are PACK, CLSK, CERT, KNBE, and VERX.
  • HSKA's SEC filings can be seen here. And to visit Heska Corp's official web site, go to www.heska.com.

HSKA Valuation Summary

  • In comparison to the median Healthcare stock, HSKA's price/sales ratio is 1.32% higher, now standing at 11.5.
  • HSKA's price/sales ratio has moved up 10.6 over the prior 243 months.
  • HSKA's price/earnings ratio has moved down 1945.6 over the prior 243 months.

Below are key valuation metrics over time for HSKA.

Stock Date P/S P/B P/E EV/EBIT
HSKA 2021-08-31 11.5 6.5 -1947.7 10302.7
HSKA 2021-08-30 11.2 6.4 -1901.9 10045.9
HSKA 2021-08-27 11.4 6.5 -1939.4 10256.0
HSKA 2021-08-26 11.4 6.5 -1942.2 10271.8
HSKA 2021-08-25 11.6 6.6 -1976.3 10462.5
HSKA 2021-08-24 11.8 6.7 -2013.1 10668.7

HSKA Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at -229.86%.
  • Its 5 year revenue growth rate is now at 13.74%.
  • Its 2 year revenue growth rate is now at -6.01%.
Over the past 34 months, HSKA's revenue has gone up $129,546,000.

The table below shows HSKA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 253.739 6.247 -1.148
2021-09-30 249.993 12.717 1.871
2021-06-30 246.389 19.593 -1.45
2021-03-31 227.173 5.442 -7.24
2020-12-31 197.323 -0.656 -14.399
2020-09-30 166.769 -1.529 -18.592

HSKA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HSKA has a Quality Grade of C, ranking ahead of 66.81% of graded US stocks.
  • HSKA's asset turnover comes in at 0.51 -- ranking 81st of 682 Pharmaceutical Products stocks.
  • NEOG, CLVS, and FLXN are the stocks whose asset turnover ratios are most correlated with HSKA.

The table below shows HSKA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.510 0.417 0.001
2021-03-31 0.525 0.411 -0.016
2020-12-31 0.522 0.412 -0.049
2020-09-30 0.492 0.423 -0.050
2020-06-30 0.473 0.430 -0.055
2020-03-31 0.504 0.447 -0.033

HSKA Price Target

For more insight on analysts targets of HSKA, see our HSKA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $282.50 Average Broker Recommendation 1.6 (Moderate Buy)

HSKA Stock Price Chart Interactive Chart >

Price chart for HSKA

HSKA Price/Volume Stats

Current price $97.55 52-week high $275.94
Prev. close $93.32 52-week low $82.92
Day low $95.58 Volume 192,951
Day high $102.97 Avg. volume 72,631
50-day MA $128.43 Dividend yield N/A
200-day MA $181.81 Market Cap 1.05B

Heska Corporation (HSKA) Company Bio

Heska Corporation sells advanced veterinary diagnostic and other specialty veterinary products, including blood testing instruments and supplies, digital imaging products, software and services, and single-use products and services such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The company was founded in 1988 and is based in Loveland, Colorado.

HSKA Latest News Stream

Event/Time News Detail
Loading, please wait...

HSKA Latest Social Stream

Loading social stream, please wait...

View Full HSKA Social Stream

Latest HSKA News From Around the Web

Below are the latest news stories about Heska Corp that investors may wish to consider to help them evaluate HSKA as an investment opportunity.

Why Earnings Season Could Be Great for Heska (HSKA)

Heska (HSKA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 24, 2022

Heska (HSKA) Expected to Beat Earnings Estimates: Should You Buy?

Heska (HSKA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on five names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. Heska Corp. recently was downgraded to Sell with a D+ rating by TheStreet's Quant Ratings.

Yahoo | February 20, 2022

Here’s a Reason to Cheer Up on Your Heska Corp. (HSKA) Position

Alger, an investment management firm, published its “Alger Small Cap Focus Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. During the fourth quarter, the largest portfolio sector weightings were Health Care and Information Technology. The largest sector overweight was Health Care. The portfolio had no exposure to the […]

Yahoo | February 18, 2022

Heska Fourth Quarter and Full Year 2021 Financial Results and Earnings Call Scheduled for February 28, 2022

Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, will report its fourth quarter and full year 2021 financial performance in a press release before the market opens on Monday, February 28, 2022. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results.

Yahoo | January 31, 2022

Read More 'HSKA' Stories Here

HSKA Price Returns

1-mo N/A
3-mo -26.15%
6-mo -45.46%
1-year -50.07%
3-year 24.86%
5-year 1.38%
YTD -46.55%
2021 25.29%
2020 51.81%
2019 11.43%
2018 7.34%
2017 12.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9081 seconds.